



MEDICAL TIPS

LIPONORM Tablets

Issue VII, No.28, 2023

Short-term Safety and Efficacy of Escalating Doses of Atorvastatin for Dyslipidemia in Children with Predialysis Chronic Kidney Disease Stage 2-5

Ramesh PL, et al. Pediatric Nephrology. 2023: 1-8.

- Dyslipidemia is risk factor in patients with chronic kidney disease (CKD) and data on safety and efficacy of statins in paediatric CKD population is limited.
- The efficacy of Atorvastatin 10 mg/day (escalation to 20 mg/day if necessary) in patients (aged 5-18 years) with CKD stage 2-5 and dyslipidemia was studied.
- Of the 31 patients enrolled, target lipid levels were achieved in 45.2% patients at a dose of 10 mg and 22 patients required dose escalation to 20 mg.
- No severe adverse events were reported with both the doses of Atorvastatin.

Atorvastatin (10-20 mg/day) is safe and effective in managing dyslipidemia in children with CKD stages 2-5.

